Search Page

1

Cite

Share

NLRC5 inhibits neointima formation following vascular injury and directly interacts with PPARγ.

Luan P, Jian W, Xu X, Kou W, Yu Q, Hu H, Li D, Wang W, Feinberg MW, Zhuang J, Xu Y, Peng W. Luan P, et al. Among authors: xu x. Nat Commun. 2019 Jun 28;10(1):2882. doi: 10.1038/s41467-019-10784-y. Nat Commun. 2019. PMID: 31253783 Free PMC article.

Cite

Share

2

Cite

Share

Hepatology Highlights.

Trivedi HD, Lau DTY, Kulai TB, Malhi H, Schwartz RE, Pisa JF, Brown RS Jr, Russo N, Nair KM, Roccaro G, Hirsova P, Gupta V, Xu X, Krisko T, Kostallari E. Trivedi HD, et al. Among authors: xu x. Hepatology. 2019 May;69(5):1849-1851. doi: 10.1002/hep.30634. Hepatology. 2019. PMID: 30977535 No abstract available.

Cite

Share

3

Cite

Share

Hepatology Highlights.

Mousa O, Malhi H, Schwartz RE, Kulai TB, Trivedi HD, Lau DTY, Shen NT, Brown RS Jr, Hirsova P, Xu X, Nicholls HT, Pisa JF, Tafesh ZH, Fortune BE, Gupta V, Kostallari E, Russo N, Jesudian AB. Mousa O, et al. Among authors: xu x. Hepatology. 2019 Mar;69(3):927-930. doi: 10.1002/hep.30569. Hepatology. 2019. PMID: 30811657 No abstract available.

Cite

Share

4

Cite

Share

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.

Clemens PL, Yan X, Lokhorst HM, Lonial S, Losic N, Khan I, Jansson R, Ahmadi T, Lantz K, Zhou H, Puchalski T, Xu XS. Clemens PL, et al. Clin Pharmacokinet. 2017 Aug;56(8):915-924. doi: 10.1007/s40262-016-0477-1. Clin Pharmacokinet. 2017. PMID: 27896689 Free PMC article. Clinical Trial.

Cite

Share

5

Cite

Share

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.

Casneuf T, Xu XS, Adams HC 3rd, Axel AE, Chiu C, Khan I, Ahmadi T, Yan X, Lonial S, Plesner T, Lokhorst HM, van de Donk NWCJ, Clemens PL, Sasser AK. Casneuf T, et al. Blood Adv. 2017 Oct 24;1(23):2105-2114. doi: 10.1182/bloodadvances.2017006866. eCollection 2017 Oct 24. Blood Adv. 2017. PMID: 29296857 Free PMC article.

Cite

Share

6

Cite

Share

Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.

Xu XS, Dimopoulos MA, Sonneveld P, Ho PJ, Belch A, Leiba M, Capra M, Gomez D, Medvedova E, Iida S, Min CK, Schecter J, Jansson R, Zhang L, Sun YN, Clemens PL. Xu XS, et al. Adv Ther. 2018 Nov;35(11):1859-1872. doi: 10.1007/s12325-018-0815-9. Epub 2018 Oct 29. Adv Ther. 2018. PMID: 30374808 Free PMC article.

Cite

Share

7

Cite

Share

Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.

Xu XS, Moreau P, Usmani SZ, Lonial S, Jakubowiak A, Oriol A, Krishnan A, Bladé J, Luo M, Sun YN, Zhou H, Nnane I, Deraedt W, Qi M, Ukropec J, Clemens PL. Xu XS, et al. Adv Ther. 2020 Apr;37(4):1464-1478. doi: 10.1007/s12325-020-01247-8. Epub 2020 Feb 20. Adv Ther. 2020. PMID: 32078124 Free PMC article. Clinical Trial.

Cite

Share

8

Cite

Share

Characterization and Neuroprotection Potential of Seleno-Polymannuronate.

Bi D, Li X, Li T, Li X, Lin Z, Yao L, Li H, Xu H, Hu Z, Zhang Z, Liu Q, Xu X. Bi D, et al. Among authors: xu x. Front Pharmacol. 2020 Feb 20;11:21. doi: 10.3389/fphar.2020.00021. eCollection 2020. Front Pharmacol. 2020. PMID: 32153394 Free PMC article.

Cite

Share

9

Cite

Share

FNDC5/Irisin inhibits pathological cardiac hypertrophy.

Yu Q, Kou W, Xu X, Zhou S, Luan P, Xu X, Li H, Zhuang J, Wang J, Zhao Y, Xu Y, Peng W. Yu Q, et al. Among authors: xu x. Clin Sci (Lond). 2019 Mar 1;133(5):611-627. doi: 10.1042/CS20190016. Print 2019 Mar 15. Clin Sci (Lond). 2019. PMID: 30782608

Cite

Share

10

Cite

Share

Chiral phosphoric acid-catalyzed asymmetric dearomatization reactions.

Xia ZL , Xu-Xu QF , Zheng C , You SL . Xia ZL , et al. Among authors: xu xu qf. Chem Soc Rev. 2020 Jan 2;49(1):286-300. doi: 10.1039/c8cs00436f. Chem Soc Rev. 2020. PMID: 31829319 Review.

Cite

Share